Advertisement

Bacterial, Fungal, and Protozoan Infection After Marrow Transplantation

  • Joel Meyers
  • Finn B. Petersen
  • George W. Counts
  • Elizabeth C. Reed
  • Shawn J. Skerrett
  • Raleigh A. Bowden
  • Keith Sullivan
  • C. Dean Buckner
Part of the Experimental Hematology Today—1987 book series (HEMATOLOGY, volume 1987)

Abstract

Bacterial, fungal, and occasionally protozoal infection continue to be important complications of marrow transplantation. Although bacterial infection as a primary cause of death is rare, such infection may add substantially to the morbidity and cost of transplantation. Moreover, bacterial infection is an important concomitant of both the treatment and outcome of acute graft versus host disease (GVHD). Fungal infection occurs less commonly than bacterial infection, but with a higher case fatality rate. Some fungi such as Aspergill us have emerged as frequent causes of death in individual transplant units [1].

Keywords

Aplastic Anemia Graft Versus Host Disease Selective Decontamination Acute Graft Versus Host Disease Chronic Graft Versus Host Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peterson PK, McGlave P, Ramsay NKC, Rhame F, Cohen E, Perry GS, Goldman AI, Kersey (1983) A prospective study of infectious diseases following bone marrow transplantation: emergence of aspergillus and cytomegalovirus as the major causes of mortality. Infect Control 4:81–89PubMedGoogle Scholar
  2. 2.
    Buckner CD, Clift RA, Sanders JE, Meyers JD, Counts GW, Farewell CT, Thomas ED and the Seattle Marrow Transplant Team (1978) Protective environment for marrow transplant recipients. A prospective study. Ann Intern Med 89:893–901PubMedGoogle Scholar
  3. 3.
    Clift RA, Sanders JE, Thomas ED, Williams B, Buckner CD (1978) Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplants. N Engl J Med 298:1052–1057PubMedCrossRefGoogle Scholar
  4. 4.
    Winston DJ, Ho WG, Young LS, Gale RP (1980) Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 68:893–897.PubMedCrossRefGoogle Scholar
  5. 5.
    Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE (1986) Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 80:884–890PubMedCrossRefGoogle Scholar
  6. 6.
    Witherspoon RP, Storb, R, Ochs HD, Flournoy N, Kopecky KJ, Sullivan KM, Deeg HJ, Sosa R, Noel DR, Atkinson K, Thomas ED (1981) Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 58:360–368PubMedGoogle Scholar
  7. 7.
    Winston DJ, Schiffman G, Wang DC, Feig SA, Lin CH, Marso EL, Ho WG, Young LS, Gale RP (1979) Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 91:835–841.PubMedGoogle Scholar
  8. 8.
    Buckner CD, Clift RA, Thomas ED, Hersman J, Sanders JE, Stewart PS, Wade JC, Murphy M, Counts G, Meyers JD (1983) Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: Effects of prophylactic measures. Infection 11:243–250PubMedCrossRefGoogle Scholar
  9. 9.
    Navari RM, Buckner CD, Clift RA, Storb R, Sanders JE, Stewart P, Sullivan KM, Williams B, Counts GW, Meyers JD, Thomas ED (1984) Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 76:564–572PubMedCrossRefGoogle Scholar
  10. 10.
    Petersen FB, Buckner CD, Clift RA, Lee S, Nelson N, Counts GW, Meyers JD, Sanders JE, Stewart PS, Bensinger WI, Navari R, Thomas ED (1986) Laminar air flow isolation and decontamination: A prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients. Infection 14:115–121PubMedCrossRefGoogle Scholar
  11. 11.
    Petersen FB, Buckner CD, Clift RA, Nelson N, Counts GW, Meyers JD, Thomas ED (1986) Prevention of nosocomial infections in marrow transplant patients: A prospective randomized comparison of systemic antibiotics versus granulocyte transfusions. Infect Control 7:586–592PubMedGoogle Scholar
  12. 12.
    Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R (1982) The effect of granulocyte transfusions upon the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 96:149–152PubMedGoogle Scholar
  13. 13.
    Clark RA, Johnson FL, Klebanoff SJ, Thomas ED (1976) Defective neutrophil Chemotaxis in bone marrow transplant patients. J Clin Invest 58:22–31PubMedCrossRefGoogle Scholar
  14. 14.
    Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP, Fefer A, Clift R, Goodell B, Thomas ED (1982) Analysis of late infections after human bone marrow transplantation: Role of genotypic non identity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 60:714–720PubMedGoogle Scholar
  15. 15.
    Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006–1010PubMedCrossRefGoogle Scholar
  16. 16.
    Petersen FB, Bowden RA, Thornquist M, Meyers JD, Buckner CD, Counts GW, Nelson MT, Newton BA, Sullivan KM, Mclver J, Thomas ED (1987) The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplantation, in pressGoogle Scholar
  17. 17.
    Winston DJ, Ho WG, Lin C-H, Bartoni K, Budinger MD, Gale RB, Champlin R (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12–18PubMedGoogle Scholar
  18. 18.
    Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, Singer J, Sullivan KM, Witherspoon RP, Thomas ED (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 302–307Google Scholar
  19. 19.
    Meyers JD, Thomas ED (1981) Infection complicating bone marrow transplantation. In: Rubin RH, Young LS (ed) Clinical Approach to infection in the immunocompromised host. New York: Plenum PressGoogle Scholar
  20. 20.
    Shepp DH, Klosterman A, Siegel MS, Meyers JD (1985) Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in the protective environment. J Infect Dis 152:1257–1263PubMedCrossRefGoogle Scholar
  21. 21.
    Winston DJ, Gale RP, Meyer DV, Young LS, and the UCLA Bone Marrow Transplantation Group (1979) Infectious complications of human bone marrow transplantation. Medicine 58:1–31PubMedCrossRefGoogle Scholar
  22. 22.
    Shepp DH, Hackman RC, Conley FK, Anderson JB, Meyers JD (1985) Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med 103:218–221PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Joel Meyers
  • Finn B. Petersen
  • George W. Counts
  • Elizabeth C. Reed
  • Shawn J. Skerrett
  • Raleigh A. Bowden
  • Keith Sullivan
  • C. Dean Buckner

There are no affiliations available

Personalised recommendations